TACR1 and cancer: Many studies have demonstrated that NK-1R antagonists counteract the side effects of chemotherapy and radiotherapy and that SP/NK-1R mediate cancer chemoresistance through Notch 1, Raf/MEK/ERK and PI3K/Akt/mTOR and MAPK signaling pathways [7,9,144].